Tien Liang BioTech Co., Ltd.
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan. The company offers Chinese medicine products, such as pills for liver and kidney deficiency, lower back pain and sore feet, dizziness and blurred vision, thirst, dry tongue and sore throat, and heel pain, as well as rheumatic pain, joint pain, generalized pain, wind-cold-dampness arthralgia, gout, neuralgia, be… Read more
Tien Liang BioTech Co., Ltd. (4127) - Total Liabilities
Latest total liabilities as of September 2025: NT$745.23 Million TWD
Based on the latest financial reports, Tien Liang BioTech Co., Ltd. (4127) has total liabilities worth NT$745.23 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tien Liang BioTech Co., Ltd. - Total Liabilities Trend (2020–2024)
This chart illustrates how Tien Liang BioTech Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tien Liang BioTech Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Tien Liang BioTech Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YeaRimDang Publishing Co. Ltd
KQ:036000
|
Korea | ₩44.64 Billion |
|
Great Elm Group Inc
NASDAQ:GEG
|
USA | $75.80 Million |
|
Y-S Electronic Co Ltd
TWO:6418
|
Taiwan | NT$470.19 Million |
|
First Nordic Metals Corp
OTCQB:FNMCF
|
USA | $4.97 Million |
|
Arogo Capital Acquisition Corp
NASDAQ:AOGO
|
USA | $9.15 Million |
|
First Bancshares Inc. (Bellevue OH)
PINK:FIBH
|
USA | $276.91 Million |
|
Groupe CRIT SA
PA:CEN
|
France | €967.94 Million |
|
Medipharm Labs Corp
OTCQX:MEDIF
|
USA | $8.74 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Tien Liang BioTech Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tien Liang BioTech Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tien Liang BioTech Co., Ltd. (2020–2024)
The table below shows the annual total liabilities of Tien Liang BioTech Co., Ltd. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$410.76 Million | +155.05% |
| 2023-12-31 | NT$161.05 Million | -20.00% |
| 2022-12-31 | NT$201.30 Million | -16.57% |
| 2021-12-31 | NT$241.30 Million | -6.36% |
| 2020-12-31 | NT$257.68 Million | -- |